ETRA Electra Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 2088082 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA—
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets4.4%
Debt / equity0.00x
Current ratio23.97x
Interest coverage—
Cash quality & payout
Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | — | — | — | — | — | — |
| R&D expense | $17.27M | — | — | $14.90M | — | — |
| Operating income | -$25.06M | — | — | -$17.02M | — | — |
| Interest expense | $0 | — | — | $1.30M | — | — |
| Net income | -$23.93M | -$26.75M | -$22.17M | -$18.09M | -$17.57M | -$7.79M |
| EPS (basic) | -3.47 | — | — | -616.86 | — | — |
| EPS (diluted) | -3.47 | — | — | -616.86 | — | — |
| Weighted avg. shares (diluted) | 6.89M | — | — | 29,329 | — | — |
| Balance sheet | ||||||
| Cash & equivalents | $256.41M | — | — | — | — | — |
| Short-term investments | $146.13M | — | — | — | — | — |
| Current assets | $406.93M | — | — | — | — | — |
| PP&E, net | $518,000 | — | — | — | — | — |
| Total assets | $410.82M | — | — | — | — | — |
| Current liabilities | $16.98M | — | — | — | — | — |
| Long-term debt | $0 | — | — | — | — | — |
| Total debt | $0 | — | — | — | — | — |
| Total liabilities | $17.92M | — | — | — | — | — |
| Shareholders' equity | $392.90M | -$219.46M | -$184.35M | -$145.51M | -$127.72M | -$110.59M |
| Net debt | -$256.41M | — | — | — | — | — |
| Shares outstanding | 62.87M | — | — | — | — | — |
| Cash flow statement | ||||||
| Operating cash flow | — | — | — | — | — | — |
| Stock-based compensation | $4.59M | — | — | $302,000 | — | — |
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.